Anteo Diagnostics Limited reported a new collaboration signed with Canadian Stock Exchange-listed Sona Nanotech Inc. where both parties will combine their respective technologies to co-develop new products that have the potential to speed up the development and improve the performance of lateral flow immunoassays. Lateral flow tests, also known as lateral flow immunoassays, are simple paper-based devices intended to detect the presence (or absence) of targets in a liquid sample without the need for specialized and costly equipment. Typically, these tests are used for medical diagnostics either for home testing, point of care (POC) testing, or laboratory clinic (eg Emergency Department) use.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.25 CAD | 0.00% | -12.28% | +4.17% |
21/05 | Sona Nanotech Appoints Chief Medical Officer, Files Provisional Conjugation Patent | MT |
21/05 | Sona Nanotech Inc. Appoints Dr. Carman Giacomantonio Md, Msc., Frcsc as Chief Medical Officer | CI |
1st Jan change | Capi. | |
---|---|---|
+4.17% | 18.03M | |
-5.81% | 180B | |
-1.63% | 106B | |
-4.14% | 67.55B | |
-6.56% | 46.11B | |
+13.22% | 45.79B | |
+2.87% | 41.61B | |
+19.93% | 31.07B | |
+10.51% | 24.77B | |
-5.36% | 24.27B |
- Stock Market
- Equities
- SONA Stock
- News Sona Nanotech Inc.
- Anteo Technologies Signs Collaboration with Sona Nanotech